Getinge AB/Skr GETI B
1D1W1MYTD1Y5YMAX
Capital at risk
About Getinge AB
Getinge AB is a Swedish company that specializes in providing products and solutions for healthcare and life sciences. The company’s core business includes the development and manufacturing of equipment and systems for intensive care, cardiovascular procedures, operating rooms, sterile reprocessing, and life science operations. Founded in 1904, Getinge is headquartered in Gothenburg, Sweden, and operates globally with a presence in numerous countries. The company's strategic positioning is strengthened by its focus on innovation and comprehensive solutions that address the complex challenges of medical and pharmaceutical processes, aiming to enhance patient outcomes and operational efficiency.
- Ticker
- Skr GETI B
- Sector
- Health
- Primary listing
- XSTO
- Employees
- 11,758
- Headquarters
- Gothenburg, Sweden
- Website
- www.getinge.com
Getinge AB Metrics
BasicAdvanced
kr 65B
24.22
kr 9.82
0.80
kr 4.75
2.00%
Price and volume
Market cap
kr 65B
Beta
0.8
52-week high
kr 248.40
52-week low
kr 175.90
Average daily volume
439K
Dividend rate
kr 4.75
Financial strength
Current ratio
1.31
Quick ratio
0.742
Long term debt to equity
0.293
Total debt to equity
0.358
Dividend payout ratio (TTM)
48.77%
Interest coverage (TTM)
8.96%
Profitability
EBITDA (TTM)
5,891
Gross margin (TTM)
48.60%
Net profit margin (TTM)
7.82%
Operating margin (TTM)
13.94%
Effective tax rate (TTM)
27.78%
Revenue per employee (TTM)
kr 2,910,000
Management effectiveness
Return on assets (TTM)
5.25%
Return on equity (TTM)
8.95%
Valuation
Price to earnings (TTM)
24.224
Price to revenue (TTM)
1.893
Price to book
2.1
Price to tangible book (TTM)
-14.06
Price to free cash flow (TTM)
17.032
Free cash flow yield (TTM)
5.87%
Free cash flow per share (TTM)
13.974
Dividend yield (TTM)
2.00%
Forward dividend yield
2.00%
Growth
Revenue change (TTM)
-3.56%
Earnings per share change (TTM)
79.60%
3-year revenue growth (CAGR)
4.79%
10-year revenue growth (CAGR)
1.45%
3-year earnings per share growth (CAGR)
7.50%
10-year earnings per share growth (CAGR)
4.82%
3-year dividend per share growth (CAGR)
3.78%
10-year dividend per share growth (CAGR)
5.43%
Bulls say / Bears say
Q2 2026 adjusted EBITA rose 49% year-on-year to SEK 1.48 bn, beating analysts’ consensus of SEK 1.37 bn, driven by a SEK 336 M tariff refund, price increases and productivity improvements, underscoring Getinge’s resilience. (Reuters)
Organic order intake grew 6.2% in Q2 2026, marking the tenth consecutive quarter of positive growth and reflecting sustained demand across acute care therapies and surgical workflows. (Reuters)
CEO Mattias Perjos purchased 25,000 Getinge shares on May 29, 2026 at SEK 187.70 per share (total SEK 4.69 M), aligning management’s interests with shareholders and signalling confidence in the company’s outlook. (Reuters)
In Q1 2026, adjusted EBITA fell 18% to SEK 824 M (vs. SEK 1,003 M in Q1 2025), missing consensus of SEK 829 M as negative currency effects (SEK –122 M) and tariff costs (SEK –104 M) weighed on profitability. (Reuters)
Ventilator sales declined and investments in project‐based, capital‐intense washers, isolators and sterilizers slowed in Q1 2026 due to heightened geopolitical uncertainty, indicating vulnerability in demand for core medical equipment. (Reuters)
Net debt rose to SEK 11.5 bn at June 30, 2026 driven by the final earn-out for Paragonix, the Pennamed acquisition and dividend payments, lifting leverage to 1.7× adjusted EBITDA and potentially limiting financial flexibility. (Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 28 Aug 2026.
Upcoming events
No upcoming events
Funds containing Getinge AB
AllEURGBPUSD
Fund name | Fund size | Skr GETI B weighting |
|---|---|---|
Xtrackers MSCI Europe Small Cap€DX2J | €3.2B | 0.33% |
Xtrackers MSCI Europe Small Cap£XXSC | £2.8B | 0.33% |
iShares STOXX Europe 600 Health Care€EXV4 | €687M | 0.28% |
iShares MSCI World Small Cap$WSML | $9B | 0.05% |
iShares MSCI World Small Cap€IUSN | €7.8B | 0.05% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.